What is it about?
The Model for End-Stage Liver Disease (MELD) has been widely used for predicting short-term mortality in patients with cirrhosis in the U.S. A modification of the MELD score was published in 2011. This was validated for Korean patients with cirrhosis.
Featured Image
Why is it important?
Clinical characteristics of cirrhosis patients are different between U.S and Korea. Modification of MELD may not be so effective. We investigated about this problem.
Perspectives
The improvement in predictive value for 3-month mortality was not definite. The Refit MELD-Na especially showed the lowest value. This result may have been due to differences in underlying etiology of cirrhosis between Korea and the U.S. Thus, a larger prospective study is warranted.
Jeong Han Kim
Konkuk University School of Medicine
Read the Original
This page is a summary of: Predictive value of Refit Model for End‐Stage Liver Disease, Refit Model for End‐Stage Liver Disease‐Na, and pre‐existing scoring s..., Journal of Gastroenterology and Hepatology, June 2013, Wiley,
DOI: 10.1111/jgh.12156.
You can read the full text:
Contributors
The following have contributed to this page
